Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fremanezumab
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Fremanezumab is a fully humanized monoclonal antibody used for the prevention of migraine headaches in adults. It works by binding to both alpha and beta isoforms of calcitonin gene-related peptide (CGRP), a neuropeptide involved in the pathophysiology of migraines, and blocks its interaction with the CGRP receptor. By inhibiting CGRP activity, fremanezumab reduces vasodilation and nociceptive signaling associated with migraine attacks. The drug is administered as a subcutaneous injection, typically on a monthly or quarterly basis. Fremanezumab was developed by Teva Pharmaceuticals and represents an important advance among anti-CGRP therapies for migraine prevention[2][3][4][5][6][7].
- Brand names
- AjovyAjovy Autoinjector
- Other names
- fremanezumab-vfrm
02
Targets
CGRP (Calcitonin gene-related peptide)
Beyond the preview
Go deeper on fremanezumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fremanezumab.